Hennion & Walsh Asset Management’s C4 Therapeutics CCCC Stock Holding History

Hennion & Walsh Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-223,168	Closed	-$587K	–	961
2026 Q1	$587K	Sell	223,168 -13,969	-6%	-$32.9K	0.02%	671
2025 Q4	$453K	Buy	237,137 +32,104	+16%	+$76.1K	0.02%	741
2025 Q3	$455K	Sell	205,033 -3,733	-2%	-$8.96K	0.02%	730
2025 Q2	$299K	Sell	208,766 -9,645	-4%	-$14K	0.01%	817
2025 Q1	$349K	Sell	218,411 -8,736	-4%	-$26.1K	0.02%	729
2024 Q4	$818K	Buy	227,147 +34,783	+18%	+$173K	0.04%	513
2024 Q3	$1.1M	Buy	192,364 +49,532	+35%	+$298K	0.05%	430
2024 Q2	$660K	Buy	+142,832	New	+$852K	0.03%	517

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hennion & Walsh Asset Management's CCCC Position: Q2 2026 in Review

Hennion & Walsh Asset Management sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 223,168 shares — an estimated $587K sold.

Hennion & Walsh Asset Management first reported a position in CCCC in Q2 2024 and held it in 8 quarters. The position peaked at $1.1M in Q3 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Hennion & Walsh Asset Management reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
Hennion & Walsh Asset Management sold 223,168 C4 Therapeutics shares in Q2 2026, an estimated $587K.
Hennion & Walsh Asset Management first reported a position in C4 Therapeutics in Q2 2024 and held it in 8 quarters.
Hennion & Walsh Asset Management's C4 Therapeutics position peaked at $1.1M in Q3 2024.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.